Successful Treatment of Vitiligo with Crisaborole 2% Ointment

William Tausend, Paige Hoyer, Morgan Arnold, Keith D. Wagner, Lindy Ross, Brandon P. Goodwin, Janice Wilson

Research output: Contribution to journalArticlepeer-review

Abstract

Vitiligo is a common disorder of skin pigmentation resulting from autoimmune destruction of melanocytes. A variety of topical and systemic treatment options have been tried with varying success. Here we describe the case of a man with refractory vitiligo successfully treated with topical crisaborole ointment. Crisaborole ointment is a topical phosphodiesterase (PDE)-4 inhibitor recently FDA-approved for the treatment of atopic dermatitis. Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo.

Original languageEnglish (US)
Pages (from-to)111-113
Number of pages3
JournalSKIN: Journal of Cutaneous Medicine
Volume3
Issue number2
DOIs
StatePublished - Mar 11 2019

Keywords

  • PDE-4 inhibitor
  • Vitiligo
  • crisaborole

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Successful Treatment of Vitiligo with Crisaborole 2% Ointment'. Together they form a unique fingerprint.

Cite this